Table A (detailed according to normotensives / hypertensives):
Baseline characteristics of the 4,912 randomised type 2 diabetes patients
according to treatment group.
| Normotensives
(n = 2177) |
Hypertensives
(n = 2735) |
|||
| Ramipril
(n = 1065) |
Placebo
(n = 1112) |
Ramipril
(n = 1378) |
Placebo
(n = 1357) |
|
| Sex (M/F) | 797 / 268 | 840 / 272 | 904 / 474 | 891 / 466 |
| Age (years) | 63.8 ( 8.6) | 63.8 (8.1) | 66.2 (8.2) | 65.9 (8.3) |
| BMI* (kg/m2) | 28.5 (4.3) | 28.4 (4.5) | 29.6 ( 4.6) | 29.8 (4.7) |
| Fasting blood glucose (mmol/L) | 9.8 (3.1) | 9.9 (3.2) | 9.5 (3.1) | 9.7 (3.3) |
| HbA1c (%) | 7.90 (1.87) | 7.76 (1.84) | 7.79 (1.80) | 7.80 (1.81) |
| Diabetes duration (years) | 9.3 (7.4) | 9.5 (7.5) | 10.1 (7.2) | 10.0 (7.4) |
| Systolic blood pressure (mmHg) | 139.7 (13.1) | 139.4 (12.9) | 151.6 (17.1) | 151.5 (17.1) |
| Diastolic blood pressure (mmHg) | 80.1 (7.9) | 80.0 (7.7) | 85.0 (9.4) | 84.9 (9.9) |
| Smoker
(³ 1 cigarette/day) |
194 (18.2) | 200 (18.0) | 177 (12.8) | 185 (13.6) |
| Alcohol consumption
(³ 1 glass/day) |
511 (48.0) | 509 (45.6) | 612 (44.4) | 626 (46.1) |
| Serum creatinine (µmol/L) | 86.2 (18.2) | 87.4 (18.2) | 91.6 (22.2) | 90.7 (20.6) |